Download
s12860-020-00294-x.pdf 2,74MB
WeightNameValue
1000 Titel
  • Identification of a druggable binding pocket in the spike protein reveals a key site for existing drugs potentially capable of combating Covid-19 infectivity
1000 Autor/in
  1. Drew, Elliot D. |
  2. Janes, Robert |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-07-01
1000 Erschienen in
1000 Quellenangabe
  • 21(1):49
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12860-020-00294-x |
1000 Ergänzendes Material
  • https://bmcmolcellbiol.biomedcentral.com/articles/10.1186/s12860-020-00294-x#Sec14 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND: Following the recent outbreak of the new coronavirus pandemic (Covid-19), the rapid determination of the structure of the homo-trimeric spike glycoprotein has prompted the study reported here. The aims were to identify potential “druggable” binding pockets in the protein and, if located, to virtual screen pharmaceutical agents currently in use for predicted affinity to these pockets which might be useful to restrict, reduce, or inhibit the infectivity of the virion. RESULTS: Our analyses of this structure have revealed a key potentially druggable pocket where it might be viable to bind pharmaceutical agents to inhibit its ability to infect human cells. This pocket is found at the inter-chain interface that exists between two domains prior to the virion binding to human Angiotensin Converting Enzyme 2 (ACE2) protein. One of these domains is the highly mobile receptor binding domain, which must move into position to interact with ACE2, which is an essential feature for viral entry to the host cell. Virtual screening with a library of purchasable drug molecules has identified pharmaceuticals currently in use as prescription and over the counter medications that, in silico, readily bind into this pocket. CONCLUSIONS: This study highlights possible drugs already in use as pharmaceuticals that may act as agents to interfere with the movements of the domains within this protein essential for the infectivity processes and hence might slow, or even halt, the infection of host cells by this new coronavirus. As these are existing pharmaceuticals already approved for use in humans, this knowledge could accelerate their roll-out, through repurposing, for affected individuals and help guide the efforts of other researchers in finding effective treatments for the disease.
1000 Sacherschließung
gnd 1206347392 COVID-19
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/RHJldywgRWxsaW90IEQu|https://orcid.org/0000-0001-5483-6282
1000 Label
1000 Förderer
  1. Biotechnology and Biological Sciences Research Council |
1000 Fördernummer
  1. BB/P024106; BB/P024106
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Biotechnology and Biological Sciences Research Council |
    1000 Förderprogramm -
    1000 Fördernummer BB/P024106; BB/P024106
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6421666.rdf
1000 Erstellt am 2020-07-02T09:37:37.541+0200
1000 Erstellt von 122
1000 beschreibt frl:6421666
1000 Bearbeitet von 122
1000 Zuletzt bearbeitet Thu Jul 02 09:39:10 CEST 2020
1000 Objekt bearb. Thu Jul 02 09:38:54 CEST 2020
1000 Vgl. frl:6421666
1000 Oai Id
  1. oai:frl.publisso.de:frl:6421666 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source